{
    "clinical_study": {
        "@rank": "43791", 
        "brief_summary": {
            "textblock": "OBJECTIVES: I. Determine the proportion of patients with cystinosis who experience a serious\n      adverse effect when treated with a new formulation of cysteamine hydrochloride for corneal\n      cystine accumulation.\n\n      II. Determine the proportion of patients with a reduction in corneal crystal density of 1.00\n      unit when treated with this regimen."
        }, 
        "brief_title": "Randomized Study of New Formulation Ophthalmic Cysteamine Hydrochloride for Corneal Cystine Accumulation in Patients With Cystinosis", 
        "completion_date": "February 2001", 
        "condition": "Cystinosis", 
        "condition_browse": {
            "mesh_term": [
                "Cystinosis", 
                "Nephrotic Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "PROTOCOL OUTLINE: This is a randomized, multicenter study Patients are randomized to receive\n      the current formulation of cysteamine hydrochloride as drops in one eye and the new\n      formulation of cysteamine hydrochloride as drops in the other eye.\n\n      Patients receive the two formulations of cysteamine hydrochloride in their assigned eyes\n      every hour during waking hours daily for 6 months (safety study) or for 1 year (efficacy\n      study)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "PROTOCOL ENTRY CRITERIA:\n\n        --Disease Characteristics--\n\n          -  Diagnosis of cystinosis with more than 2 nmole half-cystine/mg protein in leukocytes\n             OR presence of corneal crystals consistent with cystinosis and distributed in corneal\n             stroma observed by slit lamp biomicroscopy\n\n          -  Clinical history consistent with cystinosis\n\n          -  Safety study: History of adherence with current eye drop and follow-up schedule on\n             protocol #86-El-0062 Any crystal density score, including zero, on photographs, that\n             has been stable or improved over the past year\n\n          -  Efficacy study: Crystal density score at least 1.00 on photographs Concurrently on\n             cysteamine for at least the past 6 months\n\n        --Prior/Concurrent Therapy--\n\n          -  No prior cysteamine drops (efficacy study)\n\n        --Patient Characteristics--\n\n          -  Age: 1 to 50 (safety study) 2 to 12 (efficacy study)\n\n          -  Other: Willingness and ability to tolerate corneal photographs"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "50 Years", 
            "minimum_age": "1 Year"
        }, 
        "enrollment": "30", 
        "firstreceived_date": "February 2, 2001", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00010426", 
            "org_study_id": "199/15704", 
            "secondary_id": "SIGMATAU-FDR001769"
        }, 
        "intervention": {
            "intervention_name": "cysteamine hydrochloride", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Cysteamine"
        }, 
        "keyword": [
            "cystinosis", 
            "rare disease", 
            "renal and genitourinary disorders"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "overall_official": {
            "affiliation": "Sigma Tau Pharmaceuticals, Inc.", 
            "last_name": "Edward F. Lemanowicz", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "N/A", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00010426"
        }, 
        "source": "FDA Office of Orphan Products Development", 
        "sponsors": {
            "collaborator": {
                "agency": "Sigma Tau Pharmaceuticals, Inc.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "FDA Office of Orphan Products Development", 
                "agency_class": "U.S. Fed"
            }
        }, 
        "start_date": "December 1999", 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2001"
    }, 
    "geocoordinates": {}
}